Why in PACU After Prostastectomy 2016

Perioperative, Enhanced Recovery Clinical Trial

Official title:

Perioperative Mechanisms for Postoperative Function - the Case of Prostastectomy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02707614
• Other study ID #: PACU Prostastectomy 2016
• Status: Completed
• Phase: N/A
• First received: March 1, 2016
• Last updated: April 25, 2017
• Start date: February 2016
• Est. completion date: August 2016

Study information

• Verified date: April 2017
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This study aims to describe the postoperative functions of patients after undergoing open or robotic prostastectomy. Primary endpoints will focus on complications in the post-anaesthesia care unit (PACU) which prevent dischard from PACU to the general ward. This include Aldrete scores and other complications that can be registrered descriptively. Furthermore, the study seeks to compare what influence open versus robotic prostastectomy have on peri- og postoperative complications.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histology diagnosis of prostate cancer

• Surgery intended for removal or staging of prostate cancer: open prostatectomy, robotic prostastectomy, open staging surgery, laparoscopic staging surgery.

Exclusion Criteria:

• Patients with prostate cancer that do not have surgery.

• Surgery regarding only removal of distant mestatases origined from prostate cancer.

Related Conditions & MeSH terms

• Perioperative, Enhanced Recovery

Intervention

Procedure:
• Robotic vs open prostastectomy
robotic minimal invasive surgery

Locations

Country	Name	City	State
Denmark	Rigshospitalet, abdominal center	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complications	Complications assessed by aldrete score	up to 7 days